WinstonWınston
Jin Medical International logo

Jin Medical International

ZJYL
31
Medical - Instruments & Supplies · Healthcare
Price
$2.15
+0.23 (+11.98%)
Market Cap
$16.8M
Exchange
NASDAQ Capital Market
Winston Score
31
Winston is serious
Below-average fundamentals — multiple weak pillars.
Data as of Aug 10, 2026 · filings through Mar 31, 2026

Share count falling — buybacks

41.5% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 13.4M (2021) → 7.8M (2025)

Jin Medical International Ltd. is a Chinese company that makes mobility aids and rehabilitation equipment. Its main products include wheelchairs, walking aids, and related assistive devices. The company sells primarily to hospitals, rehabilitation centers, and individual patients across China, serving an aging population that increasingly needs help with movement and daily living.

Jin Medical earns revenue by manufacturing and selling its products directly and through distributors. It operates mainly in China, which is one of the world's largest and fastest-growing markets for elderly care products due to its rapidly aging population. The company is small, with a near-zero market cap, thin operating margins around 2%, and a very low return on invested capital, which suggests limited pricing power and intense competition from both domestic and international medical device makers. The key risk is that the company must scale efficiently in a crowded market while managing costs, as its current profitability leaves little room for error.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-9.7% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-15.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$2M/ year

Flat (+4% vs prior year)

7.5% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

76.6%ownership

Insiders own a meaningful stake in the company

Cash Runway

~3 years

$30M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

$30M cash & investments at current burn rate

Revenue declining

Jin Medical International's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
26.9%
Modest — 26.9% gross margin
Operating Margin
-7.2%
Losing money on operations — -7.2%
ROCE
-1.3%
Weak — -1.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-13.6%
Shrinking sales (-13.6% YoY)
EPS YoY
-35.9%
Earnings shrinking (-35.9% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
-51%
Weak — only -51% of profit becomes cash
FCF Margin
-35.3%
Burning cash (-35.3%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.68
Moderate — manageable debt (0.68)
Interest Cover
100.00x
Comfortably covers interest (100.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
14.7x
Attractive valuation — P/E 14.7

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial